<p>StockNews.com 的股票分析師在週六發佈的一份報告中開始覆蓋 Intra-Cellular Therapies (NASDAQ:ITCI - 獲取免費報告) 的股票。該經紀公司對這家生物製藥公司的股票給予了 “持有” 評級。</p>
<ul>
<li>MarketBeat 週迴顧 – 01/13 - 01/17</li>
</ul>
<p>其他分析師最近也對該股票發佈了報告。瑞穗證券將 Intra-Cellular Therapies 的股票評級從 “跑贏大盤” 下調至 “中性”，並在 2 月 24 日的研究報告中將其目標價從 140.00 美元下調至 132.00 美元。貝爾德 R W 在 1 月 13 日的研究報告中將 Intra-Cellular Therapies 的評級從 “強力買入” 下調至 “持有”。加拿大皇家銀行在 1 月 22 日的報告中重新發布了 “行業表現” 評級，並將 Intra-Cellular Therapies 的目標價設定為 132.00 美元（上調自 108.00 美元）。派珀·桑德勒在 1 月 14 日的研究報告中重申了 “中性” 評級，並將 Intra-Cellular Therapies 的目標價上調至 132.00 美元（之前為 107.00 美元）。最後，Leerink Partners 在 1 月 13 日的研究報告中將 Intra-Cellular Therapies 的評級從 “強力買入” 下調至 “持有”。共有 11 位分析師對該股票給予了持有評級，5 位分析師給予了買入評級。根據 MarketBeat 的數據，Intra-Cellular Therapies 目前的平均評級為 “持有”，共識目標價為 106.23 美元。</p>
<p><strong>獲取我們關於 ITCI 的最新研究報告</strong></p>
<h2>Intra-Cellular Therapies 股票表現</h2>
<ul>
<li>強生股票是否準備回報長期持有者？</li>
</ul>
<p>NASDAQ ITCI 週五開盤價為 131.87 美元。該公司的 50 日移動平均線為 129.62 美元，200 日移動平均線為 101.43 美元。Intra-Cellular Therapies 的 52 周低點為 64.09 美元，52 周高點為 131.98 美元。該公司的市值為 140.5 億美元，市盈率為 -151.57，貝塔值為 0.69。</p>
<p>Intra-Cellular Therapies (NASDAQ:ITCI - 獲取免費報告) 最近在 2 月 21 日發佈了季度財報。這家生物製藥公司報告的每股收益為（0.16）美元，低於分析師的共識預期（0.08）美元，差距為（0.08）美元。該季度的收入為 1.9922 億美元，而分析師的預期為 2.0508 億美元。Intra-Cellular Therapies 的淨利潤率為 -14.07%，股本回報率為 -9.93%。平均而言，賣方分析師預測 Intra-Cellular Therapies 在當前年度的每股收益為 -0.64。</p>
<h2>機構投資者對 Intra-Cellular Therapies 的看法</h2>
<ul>
<li>百時美施貴寶的大額收購：在 2 筆生物技術交易中達 181 億美元</li>
</ul>
<p>幾家大型投資者最近買入和賣出了該公司的股票。MassMutual Private Wealth &amp; Trust FSB 在第一季度將其在 Intra-Cellular Therapies 的持股增加了 124.3%。MassMutual Private Wealth &amp; Trust FSB 目前擁有 240 股該生物製藥公司的股票，價值 32,000 美元，此前在上個季度又購買了 133 股。威靈頓管理集團在第四季度將其在 Intra-Cellular Therapies 的持股增加了 1.6%。威靈頓管理集團目前擁有 1,033,743 股該生物製藥公司的股票，價值 86,338,000 美元，此前在此期間又收購了 16,096 股。Wealth Enhancement Advisory Services LLC 在第四季度將其在 Intra-Cellular Therapies 的持股增加了 36.3%。Wealth Enhancement Advisory Services LLC 目前擁有 12,010 股該生物製藥公司的股票，價值 1,003,000 美元，此前在上個季度又購買了 3,200 股。Universal Beteiligungs und Servicegesellschaft mbH 在第四季度購買了 Intra-Cellular Therapies 的新股份，價值約 7,951,000 美元。最後，GF Fund Management CO. LTD. 在第四季度購買了 Intra-Cellular Therapies 的新股份，價值約 186,000 美元。機構投資者持有該公司 92.33% 的股票。</p>
<h2>關於 Intra-Cellular Therapies</h2>
<p>(獲取免費報告)</p>
<p>Intra-Cellular Therapies, Inc 是一家生物製藥公司，專注於發現、臨牀開發和商業化小分子藥物，主要針對神經精神和神經系統疾病的醫療需求，通過靶向美國中樞神經系統 (CNS) 的細胞內信號機制。</p>
<h2>瞭解更多</h2>
<ul>
<li>我們更看好的五隻股票超過 Intra-Cellular Therapies</li>
<li>投資旅遊股票的好處</li>
<li>Archer Aviation 在非洲的交易可能提升 ACHR 股票</li>
<li>頂級生物技術股票：探索創新機會</li>
<li>空頭賣家對這三隻半導體股票是否錯誤？</li>
<li>電動車股票及其盈利方式</li>
<li>波音在 3 月獲得 500 億美元訂單——BA 股票現在值得買嗎？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SVRDSQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SVRDSQ"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Intra-Cellular Therapies 嗎？</h2>
<p>在你考慮 Intra-Cellular Therapies 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦購買，以便在更廣泛的市場注意到之前... 而 Intra-Cellular Therapies 並不在名單上。</p>
<p>雖然 Intra-Cellular Therapies 目前在分析師中獲得了持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

ITCI

<p>Intra-Cellular Therapies（納斯達克代碼：ITCI）獲得了 StockNews.com 的 “持有” 評級，該公司最近開始對該股票進行覆蓋。其他分析師也調整了他們的評級，瑞穗將其下調至 “中性”，貝爾德將其下調至 “持有”。該股票的平均評級目前為 “持有”，共識目標價為 106.23 美元。該公司報告的季度每股虧損為 0.16 美元，未能達到預期，市值為 140.5 億美元</p>

<p>Stock analysts at StockNews.com assumed coverage on shares of Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) in a report released on Saturday. The brokerage set a &#34;hold&#34; rating on the biopharmaceutical company's stock.</p>
<div class="lb-trans"><p>StockNews.com 的股票分析師在週六發佈的一份報告中開始覆蓋 Intra-Cellular Therapies (NASDAQ:ITCI - 獲取免費報告) 的股票。該經紀公司對這家生物製藥公司的股票給予了 “持有” 評級。</p>
</div><ul>
<li>MarketBeat Week in Review – 01/13 - 01/17</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 週迴顧 – 01/13 - 01/17</li>
</ul>
</div><p>Other analysts have also recently issued reports about the stock. Mizuho cut shares of Intra-Cellular Therapies from an &#34;outperform&#34; rating to a &#34;neutral&#34; rating and reduced their price objective for the stock from $140.00 to $132.00 in a research note on Monday, February 24th. Baird R W lowered Intra-Cellular Therapies from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research note on Monday, January 13th. Royal Bank of Canada reissued a &#34;sector perform&#34; rating and set a $132.00 price target (up from $108.00) on shares of Intra-Cellular Therapies in a report on Wednesday, January 22nd. Piper Sandler reaffirmed a &#34;neutral&#34; rating and issued a $132.00 price objective (up previously from $107.00) on shares of Intra-Cellular Therapies in a research note on Tuesday, January 14th. Finally, Leerink Partnrs cut Intra-Cellular Therapies from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research report on Monday, January 13th. Eleven analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. According to MarketBeat, Intra-Cellular Therapies currently has an average rating of &#34;Hold&#34; and a consensus target price of $106.23.</p>
<div class="lb-trans"><p>其他分析師最近也對該股票發佈了報告。瑞穗證券將 Intra-Cellular Therapies 的股票評級從 “跑贏大盤” 下調至 “中性”，並在 2 月 24 日的研究報告中將其目標價從 140.00 美元下調至 132.00 美元。貝爾德 R W 在 1 月 13 日的研究報告中將 Intra-Cellular Therapies 的評級從 “強力買入” 下調至 “持有”。加拿大皇家銀行在 1 月 22 日的報告中重新發布了 “行業表現” 評級，並將 Intra-Cellular Therapies 的目標價設定為 132.00 美元（上調自 108.00 美元）。派珀·桑德勒在 1 月 14 日的研究報告中重申了 “中性” 評級，並將 Intra-Cellular Therapies 的目標價上調至 132.00 美元（之前為 107.00 美元）。最後，Leerink Partners 在 1 月 13 日的研究報告中將 Intra-Cellular Therapies 的評級從 “強力買入” 下調至 “持有”。共有 11 位分析師對該股票給予了持有評級，5 位分析師給予了買入評級。根據 MarketBeat 的數據，Intra-Cellular Therapies 目前的平均評級為 “持有”，共識目標價為 106.23 美元。</p>
</div><p><strong>Get Our Latest Research Report on ITCI</strong></p>
<div class="lb-trans"><p><strong>獲取我們關於 ITCI 的最新研究報告</strong></p>
</div><h2>Intra-Cellular Therapies Stock Performance</h2>
<div class="lb-trans"><h2>Intra-Cellular Therapies 股票表現</h2>
</div><ul>
<li>Is Johnson &amp; Johnson Stock Set to Reward Long-Term Holders?</li>
</ul>
<div class="lb-trans"><ul>
<li>強生股票是否準備回報長期持有者？</li>
</ul>
</div><p>NASDAQ ITCI opened at $131.87 on Friday. The business's fifty day moving average is $129.62 and its 200 day moving average is $101.43. Intra-Cellular Therapies has a fifty-two week low of $64.09 and a fifty-two week high of $131.98. The company has a market capitalization of $14.05 billion, a PE ratio of -151.57 and a beta of 0.69.</p>
<div class="lb-trans"><p>NASDAQ ITCI 週五開盤價為 131.87 美元。該公司的 50 日移動平均線為 129.62 美元，200 日移動平均線為 101.43 美元。Intra-Cellular Therapies 的 52 周低點為 64.09 美元，52 周高點為 131.98 美元。該公司的市值為 140.5 億美元，市盈率為 -151.57，貝塔值為 0.69。</p>
</div><p>Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) last posted its quarterly earnings data on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.08). The company had revenue of $199.22 million for the quarter, compared to analysts' expectations of $205.08 million. Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. On average, sell-side analysts forecast that Intra-Cellular Therapies will post -0.64 EPS for the current year.</p>
<div class="lb-trans"><p>Intra-Cellular Therapies (NASDAQ:ITCI - 獲取免費報告) 最近在 2 月 21 日發佈了季度財報。這家生物製藥公司報告的每股收益為（0.16）美元，低於分析師的共識預期（0.08）美元，差距為（0.08）美元。該季度的收入為 1.9922 億美元，而分析師的預期為 2.0508 億美元。Intra-Cellular Therapies 的淨利潤率為 -14.07%，股本回報率為 -9.93%。平均而言，賣方分析師預測 Intra-Cellular Therapies 在當前年度的每股收益為 -0.64。</p>
</div><h2>Institutional Investors Weigh In On Intra-Cellular Therapies</h2>
<div class="lb-trans"><h2>機構投資者對 Intra-Cellular Therapies 的看法</h2>
</div><ul>
<li>Bristol Myers Squibb’s big buys: $18.1 billion in 2 biotech deals</li>
</ul>
<div class="lb-trans"><ul>
<li>百時美施貴寶的大額收購：在 2 筆生物技術交易中達 181 億美元</li>
</ul>
</div><p>Several large investors have recently bought and sold shares of the business. MassMutual Private Wealth &amp; Trust FSB increased its holdings in shares of Intra-Cellular Therapies by 124.3% in the 1st quarter. MassMutual Private Wealth &amp; Trust FSB now owns 240 shares of the biopharmaceutical company's stock worth $32,000 after buying an additional 133 shares during the last quarter. Wellington Management Group LLP raised its stake in shares of Intra-Cellular Therapies by 1.6% in the fourth quarter. Wellington Management Group LLP now owns 1,033,743 shares of the biopharmaceutical company's stock valued at $86,338,000 after acquiring an additional 16,096 shares during the period. Wealth Enhancement Advisory Services LLC grew its holdings in Intra-Cellular Therapies by 36.3% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 12,010 shares of the biopharmaceutical company's stock valued at $1,003,000 after purchasing an additional 3,200 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in Intra-Cellular Therapies in the 4th quarter worth about $7,951,000. Finally, GF Fund Management CO. LTD. purchased a new stake in Intra-Cellular Therapies in the 4th quarter worth about $186,000. Institutional investors own 92.33% of the company's stock.</p>
<div class="lb-trans"><p>幾家大型投資者最近買入和賣出了該公司的股票。MassMutual Private Wealth &amp; Trust FSB 在第一季度將其在 Intra-Cellular Therapies 的持股增加了 124.3%。MassMutual Private Wealth &amp; Trust FSB 目前擁有 240 股該生物製藥公司的股票，價值 32,000 美元，此前在上個季度又購買了 133 股。威靈頓管理集團在第四季度將其在 Intra-Cellular Therapies 的持股增加了 1.6%。威靈頓管理集團目前擁有 1,033,743 股該生物製藥公司的股票，價值 86,338,000 美元，此前在此期間又收購了 16,096 股。Wealth Enhancement Advisory Services LLC 在第四季度將其在 Intra-Cellular Therapies 的持股增加了 36.3%。Wealth Enhancement Advisory Services LLC 目前擁有 12,010 股該生物製藥公司的股票，價值 1,003,000 美元，此前在上個季度又購買了 3,200 股。Universal Beteiligungs und Servicegesellschaft mbH 在第四季度購買了 Intra-Cellular Therapies 的新股份，價值約 7,951,000 美元。最後，GF Fund Management CO. LTD. 在第四季度購買了 Intra-Cellular Therapies 的新股份，價值約 186,000 美元。機構投資者持有該公司 92.33% 的股票。</p>
</div><h2>About Intra-Cellular Therapies</h2>
<div class="lb-trans"><h2>關於 Intra-Cellular Therapies</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(獲取免費報告)</p>
</div><p>Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.</p>
<div class="lb-trans"><p>Intra-Cellular Therapies, Inc 是一家生物製藥公司，專注於發現、臨牀開發和商業化小分子藥物，主要針對神經精神和神經系統疾病的醫療需求，通過靶向美國中樞神經系統 (CNS) 的細胞內信號機制。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>瞭解更多</h2>
</div><ul>
<li>Five stocks we like better than Intra-Cellular Therapies</li>
<li>Investing in Travel Stocks Benefits</li>
<li>Archer Aviation’s Africa Deal Could Boost ACHR Stock</li>
<li>Top Biotech Stocks: Exploring Innovation Opportunities</li>
<li>Are Short Sellers Wrong About These 3 Semiconductor Stocks?</li>
<li>EV Stocks and How to Profit from Them</li>
<li>Boeing Gets $50B in March Orders—Is BA Stock a Buy Now?</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票超過 Intra-Cellular Therapies</li>
<li>投資旅遊股票的好處</li>
<li>Archer Aviation 在非洲的交易可能提升 ACHR 股票</li>
<li>頂級生物技術股票：探索創新機會</li>
<li>空頭賣家對這三隻半導體股票是否錯誤？</li>
<li>電動車股票及其盈利方式</li>
<li>波音在 3 月獲得 500 億美元訂單——BA 股票現在值得買嗎？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SVRDSQ" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=ITCI"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Intra-Cellular Therapies Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Intra-Cellular Therapies 嗎？</h2>
</div><p>Before you consider Intra-Cellular Therapies, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Intra-Cellular Therapies 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Intra-Cellular Therapies wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦購買，以便在更廣泛的市場注意到之前... 而 Intra-Cellular Therapies 並不在名單上。</p>
</div><p>While Intra-Cellular Therapies currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Intra-Cellular Therapies 目前在分析師中獲得了持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Intra-Cellular Therapies（納斯達克股票代碼：ITCI）獲得 StockNews.com 分析師的持有評級